212 related articles for article (PubMed ID: 36967154)
1. Myeloid-derived suppressor cells in head and neck squamous cell carcinoma.
He JY; Huo FY; Tang HC; Liu B; Bu LL
Int Rev Cell Mol Biol; 2023; 375():33-92. PubMed ID: 36967154
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.
Liu JF; Deng WW; Chen L; Li YC; Wu L; Ma SR; Zhang WF; Bu LL; Sun ZJ
Mol Carcinog; 2018 Mar; 57(3):429-439. PubMed ID: 29215754
[TBL] [Abstract][Full Text] [Related]
3. Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck.
Chen WC; Lai CH; Chuang HC; Lin PY; Chen MF
Head Neck; 2017 Feb; 39(2):347-355. PubMed ID: 27696591
[TBL] [Abstract][Full Text] [Related]
4. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
[TBL] [Abstract][Full Text] [Related]
5. Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma.
Mao L; Fan TF; Wu L; Yu GT; Deng WW; Chen L; Bu LL; Ma SR; Liu B; Bian Y; Kulkarni AB; Zhang WF; Sun ZJ
J Cell Mol Med; 2017 Sep; 21(9):2199-2210. PubMed ID: 28401653
[TBL] [Abstract][Full Text] [Related]
6. VISTA blockade alleviates immunosuppression of MDSCs in oral squamous cell carcinoma.
Liu J; Lin WP; Xiao Y; Yang QC; Bushabu Fidele N; Yu HJ; Sun ZJ
Int Immunopharmacol; 2023 Dec; 125(Pt A):111128. PubMed ID: 37907049
[TBL] [Abstract][Full Text] [Related]
7. Novel mucoadhesive celecoxib-loaded cubosomal sponges: Anticancer potential and regulation of myeloid-derived suppressor cells in oral squamous cell carcinoma.
Mabrouk AA; El-Mezayen NS; Tadros MI; El-Gazayerly ON; El-Refaie WM
Eur J Pharm Biopharm; 2023 Jan; 182():62-80. PubMed ID: 36513316
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC.
Liu J; Lin WP; Su W; Wu ZZ; Yang QC; Wang S; Sun TG; Huang CF; Wang XL; Sun ZJ
Int Immunopharmacol; 2023 Jun; 119():110243. PubMed ID: 37137265
[TBL] [Abstract][Full Text] [Related]
9. CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.
Agresta L; Lehn M; Lampe K; Cantrell R; Hennies C; Szabo S; Wise-Draper T; Conforti L; Hoebe K; Janssen EM
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217758
[TBL] [Abstract][Full Text] [Related]
10. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.
Weed DT; Vella JL; Reis IM; De la Fuente AC; Gomez C; Sargi Z; Nazarian R; Califano J; Borrello I; Serafini P
Clin Cancer Res; 2015 Jan; 21(1):39-48. PubMed ID: 25320361
[TBL] [Abstract][Full Text] [Related]
11. STAT3 promotes differentiation of monocytes to MDSCs via CD39/CD73-adenosine signal pathway in oral squamous cell carcinoma.
Cui H; Lan Z; Zou KL; Zhao YY; Yu GT
Cancer Immunol Immunother; 2023 May; 72(5):1315-1326. PubMed ID: 36436019
[TBL] [Abstract][Full Text] [Related]
12. Myeloid-derived suppressor cells and plasmacytoid dendritic cells are associated with oncogenesis of oral squamous cell carcinoma.
Kouketsu A; Haruka S; Kuroda K; Hitoshi M; Kensuke Y; Tsuyoshi S; Takahashi T; Hiroyuki K
J Oral Pathol Med; 2023 Jan; 52(1):9-19. PubMed ID: 36380437
[TBL] [Abstract][Full Text] [Related]
13. γ-Secretase inhibitor reduces immunosuppressive cells and enhances tumour immunity in head and neck squamous cell carcinoma.
Mao L; Zhao ZL; Yu GT; Wu L; Deng WW; Li YC; Liu JF; Bu LL; Liu B; Kulkarni AB; Zhang WF; Zhang L; Sun ZJ
Int J Cancer; 2018 Mar; 142(5):999-1009. PubMed ID: 29047105
[TBL] [Abstract][Full Text] [Related]
14. CD73 expression in myeloid-derived suppressor cells is correlated with clinical stages in head and neck squamous cell carcinomas.
Zheng W; Zhu Y; Chen X; Zhao J
Ann Transl Med; 2021 Jul; 9(14):1148. PubMed ID: 34430589
[TBL] [Abstract][Full Text] [Related]
15. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy.
Li X; Zhong J; Deng X; Guo X; Lu Y; Lin J; Huang X; Wang C
Front Immunol; 2021; 12():754196. PubMed ID: 35003065
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of targeting MDSCs in tumor microenvironment.
Sui H; Dongye S; Liu X; Xu X; Wang L; Jin CQ; Yao M; Gong Z; Jiang D; Zhang K; Liu Y; Liu H; Jiang G; Su Y
Front Immunol; 2022; 13():990463. PubMed ID: 36131911
[TBL] [Abstract][Full Text] [Related]
17. The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.
Weed DT; Zilio S; Reis IM; Sargi Z; Abouyared M; Gomez-Fernandez CR; Civantos FJ; Rodriguez CP; Serafini P
Front Immunol; 2019; 10():1206. PubMed ID: 31214178
[TBL] [Abstract][Full Text] [Related]
18. LncRNAs as an intermediate in HPV16 promoting myeloid-derived suppressor cell recruitment of head and neck squamous cell carcinoma.
Ma X; Sheng S; Wu J; Jiang Y; Gao X; Cen X; Wu J; Wang S; Tang Y; Tang Y; Liang X
Oncotarget; 2017 Jun; 8(26):42061-42075. PubMed ID: 28159935
[TBL] [Abstract][Full Text] [Related]
19. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.
Yu GT; Bu LL; Huang CF; Zhang WF; Chen WJ; Gutkind JS; Kulkarni AB; Sun ZJ
Oncotarget; 2015 Dec; 6(39):42067-80. PubMed ID: 26573233
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.
Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
